Milbank LLP represented Bank of America, N.A. and BofA Securities as Sole Global Coordinator and Sole Book-Running Manager in connection with the incurrence of $705 million 4.750% senior notes due 2028 and €1.4 billion 3.875% senior notes due 2028 (collectively, the “Notes”) to support the acquisition of German public company Biotest AG by Spanish public company Grifols, S.A. (“Grifols”) (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), by way of tender offer. Milbank also represented Bank of America, N.A. in providing a bridge loan commitment to Grifols backstopping the Notes.
Headquartered in Barcelona, Spain, Grifols is a leading global producer of plasma medicines with a presence in more than 100 countries. Biotest AG is a European healthcare company specializing in innovative hematology and clinical immunology.
The Milbank team was led by New York-based Global Leveraged Finance partner Marcus Dougherty, Capital Markets partner Jonathon Jackson, Frankfurt-based Global Leveraged Finance partner Thomas Ingenhoven, along with special counsel Meir Hornung and with assistance from associates Alex Becker, Gerrit Merkel, Sebastian Trompler, Mitch Cooper and Ian Hunley.
